

FIRST REGULAR SESSION

HOUSE BILL NO. 436

95TH GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVES ROORDA (Sponsor), CASEY,
ATKINS AND SCHIEFFER (Co-sponsors).

0303L.01I

D. ADAM CRUMBLISS, Chief Clerk

AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to schedule II controlled substances, with a penalty provision.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

(1) Has high potential for abuse; and

(2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

(1) The controlled substances listed in this subsection are included in Schedule I;

(2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(a) Acetyl-alpha-methylfentanyl;

(b) Acetylmethadol;

(c) Allylprodine;

(d) Alphacetylmethadol;

(e) Alphameprodine;

(f) Alphamethadol;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

- 17 (g) Alpha-methylfentanyl;
- 18 (h) Alpha-methylthiofentanyl;
- 19 (i) Benzethidine;
- 20 (j) Betacetylmethadol;
- 21 (k) Beta-hydroxyfentanyl;
- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxin;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoperidine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacymorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;
- 52 (pp) Para-fluorofentanyl;

- 53 (qq) PEPAP;
- 54 (rr) Phenadoxone;
- 55 (ss) Phenampromide;
- 56 (tt) Phenomorphan;
- 57 (uu) Phenoperidine;
- 58 (vv) Piritramide;
- 59 (ww) Proheptazine;
- 60 (xx) Properidine;
- 61 (yy) Propiram;
- 62 (zz) Racemoramide;
- 63 (aaa) Thiofentanyl;
- 64 (bbb) Tilidine;
- 65 (ccc) Trimeperidine;

66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers
68 is possible within the specific chemical designation:

- 69 (a) Acetorphine;
- 70 (b) Acetyldihydrocodeine;
- 71 (c) Benzylmorphine;
- 72 (d) Codeine methylbromide;
- 73 (e) Codeine-N-Oxide;
- 74 (f) Cyprenorphine;
- 75 (g) Desomorphine;
- 76 (h) Dihydromorphine;
- 77 (i) Drotebanol;
- 78 (j) Etorphine (except hydrochloride salt);
- 79 (k) Heroin;
- 80 (l) Hydromorphanol;
- 81 (m) Methyldesorphine;
- 82 (n) Methyldihydromorphine;
- 83 (o) Morphine methylbromide;
- 84 (p) Morphine methylsulfonate;
- 85 (q) Morphine-N-Oxide;
- 86 (r) Myrophine;
- 87 (s) Nicocodeine;
- 88 (t) Nicomorphine;

- 89 (u) Normorphine;
90 (v) Pholcodine;
91 (w) Thebacon;
92 (4) Any material, compound, mixture or preparation which contains any quantity of the
93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
95 the specific chemical designation:
96 (a) 4-bromo-2, 5-dimethoxyamphetamine;
97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
98 (c) 2,5-dimethoxyamphetamine;
99 (d) 2,5-dimethoxy-4-ethylamphetamine;
100 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
101 (f) 4-methoxyamphetamine;
102 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
103 (h) 4-methyl-2, 5-dimethoxyamphetamine;
104 (i) 3,4-methylenedioxyamphetamine;
105 (j) 3,4-methylenedioxymethamphetamine;
106 (k) 3,4-methylenedioxy-N-ethylamphetamine;
107 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
108 (m) 3,4,5-trimethoxyamphetamine;
109 (n) Alpha-ethyltryptamine;
110 (o) Alpha-methyltryptamine;
111 (p) Bufotenine;
112 (q) Diethyltryptamine;
113 (r) Dimethyltryptamine;
114 (s) 5-methoxy-N,N-diisopropyltryptamine;
115 (t) Ibogaine;
116 (u) Lysergic acid diethylamide;
117 (v) Marijuana or marihuana;
118 (w) Mescaline;
119 (x) Parahexyl;
120 (y) Peyote, to include all parts of the plant presently classified botanically as Lophophora
121 Williamsil Lemaire, whether growing or not; the seeds thereof; any extract from any part of such
122 plant; and every compound, manufacture, salt, derivative, mixture or preparation of the plant,
123 its seed or extracts;
124 (z) N-ethyl-3-piperidyl benzilate;

- 125 (aa) N-methyl-3-piperidyl benzilate;
126 (bb) Psilocybin;
127 (cc) Psilocyn;
128 (dd) Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis
129 (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis
130 plant, or in the resinous extractives of such plant, or synthetic substances, derivatives, and their
131 isomers with similar chemical structure and pharmacological activity to those substances
132 contained in the plant, such as the following:
133 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
134 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
135 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
136 d. Any compounds of these structures, regardless of numerical designation of atomic
137 positions covered;
138 (ee) Ethylamine analog of phencyclidine;
139 (ff) Pyrrolidine analog of phencyclidine;
140 (gg) Thiophene analog of phencyclidine;
141 (hh) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
142 (ii) Salvia divinorum;
143 (jj) Salvinorin A;
144 (5) Any material, compound, mixture or preparation containing any quantity of the
145 following substances having a depressant effect on the central nervous system, including their
146 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of
147 isomers is possible within the specific chemical designation:
148 (a) Gamma-hydroxybutyric acid;
149 (b) Mecloqualone;
150 (c) Methaqualone;
151 (6) Any material, compound, mixture or preparation containing any quantity of the
152 following substances having a stimulant effect on the central nervous system, including their
153 salts, isomers and salts of isomers:
154 (a) Aminorex;
155 (b) N-benzylpiperazine;
156 (c) Cathinone;
157 (d) Fenethylline;
158 (e) Methcathinone;
159 (f) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazoline);
160 (g) N-ethylamphetamine;

- 161 (h) N,N-dimethylamphetamine;
- 162 (7) A temporary listing of substances subject to emergency scheduling under federal law
- 163 shall include any material, compound, mixture or preparation which contains any quantity of the
- 164 following substances:
- 165 (a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its optical isomers,
- 166 salts and salts of isomers;
- 167 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
- 168 optical isomers, salts and salts of isomers;
- 169 (8) Khat, to include all parts of the plant presently classified botanically as *catha edulis*,
- 170 whether growing or not; the seeds thereof; any extract from any part of such plant; and every
- 171 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.
- 172 3. The department of health and senior services shall place a substance in Schedule II
- 173 if it finds that:
- 174 (1) The substance has high potential for abuse;
- 175 (2) The substance has currently accepted medical use in treatment in the United States,
- 176 or currently accepted medical use with severe restrictions; and
- 177 (3) The abuse of the substance may lead to severe psychic or physical dependence.
- 178 4. The controlled substances listed in this subsection are included in Schedule II:
- 179 (1) Any of the following substances whether produced directly or indirectly by extraction
- 180 from substances of vegetable origin, or independently by means of chemical synthesis, or by
- 181 combination of extraction and chemical synthesis:
- 182 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
- 183 opiate, excluding apomorphine, thebaine-derived butorphanol, dextrophan, nalbuphine,
- 184 nalmeferene, naloxone and naltrexone, and their respective salts but including the following:
- 185 a. Raw opium;
- 186 b. Opium extracts;
- 187 c. Opium fluid;
- 188 d. Powdered opium;
- 189 e. Granulated opium;
- 190 f. Tincture of opium;
- 191 g. Codeine;
- 192 h. Ethylmorphine;
- 193 i. Etorphine hydrochloride;
- 194 j. Hydrocodone;
- 195 k. Hydromorphone;
- 196 l. Metopon;

- 197 m. Morphine;
198 n. Oxycodone;
199 o. Oxymorphone;
200 p. Thebaine;
201 (b) Any salt, compound, derivative, or preparation thereof which is chemically
202 equivalent or identical with any of the substances referred to in this subdivision, but not
203 including the isoquinoline alkaloids of opium;
204 (c) Opium poppy and poppy straw;
205 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
206 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
207 with any of these substances, but not including decocainized coca leaves or extractions which
208 do not contain cocaine or ecgonine;
209 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
210 or powder form which contains the phenanthrene alkaloids of the opium poppy);
211 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
212 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
213 the specific chemical designation, dextrorphan and levopropoxyphene excepted:
214 (a) Alfentanil;
215 (b) Alphaprodine;
216 (c) **Amyl nitrate**;
217 (d) Anileridine;
218 [(d)] (e) Bezitramide;
219 [(e) Bulk dextropropoxyphene;]
220 (f) **Butyl nitrite**;
221 (g) Carfentanil;
222 (h) **Cyclohexyl nitrite**;
223 [(g) Butyl nitrite;] (i) **Bulk Dextropropoxypene**;
224 [(h)] (j) Dihydrocodeine;
225 [(i)] (k) Diphenoxylate;
226 (l) **Ethyl nitrite**;
227 [(j)] (m) Fentanyl;
228 (n) **Isoamyl nitrite**;
229 (o) **Isobutyl nitrite**;
230 (p) **Isoethyl nitrite**;
231 (q) **Isopentyl nitrite**;
232 (r) **Isopropyl nitrite**;

- 233 [(k)] (s) Isomethadone;
234 [(l)] (t) Levo-alphaacetylmethadol;
235 [(m)] (u) Levomethorphan;
236 [(n)] (v) Levorphanol;
237 [(o)] (w) Metazocine;
238 [(p)] (x) Methadone;
239 [(q)] (y) Meperidine;
240 [(r)] (z) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
241 (aa) **Pentyl nitrite**;
242 [(s)] (bb) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--
243 carboxylic acid;
244 [(t)] (cc) Pethidine (meperidine);
245 [(u)] (dd) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
246 [(v)] (ee) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
247 [(w)] (ff) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
248 [(x)] (gg) Phenazocine;
249 [(y)] (hh) Piminodine;
250 (ii) **Propyl nitrite**;
251 [(z)] (jj) Racemethorphan;
252 [(aa)] (kk) Racemorphan;
253 [(bb)] (ll) Remifentanil;
254 [(cc)] (mm) Sufentanil;
255 (3) Any material, compound, mixture, or preparation which contains any quantity of the
256 following substances having a stimulant effect on the central nervous system:
257 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
258 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
259 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
260 (d) Phenmetrazine and its salts;
261 (e) Methylphenidate;
262 (4) Any material, compound, mixture, or preparation which contains any quantity of the
263 following substances having a depressant effect on the central nervous system, including its salts,
264 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
265 is possible within the specific chemical designation:
266 (a) Amobarbital;
267 (b) Glutethimide;
268 (c) Pentobarbital;

269 (d) Phencyclidine;
270 (e) Secobarbital;
271 (5) Any material or compound which contains any quantity of nabilone;
272 (6) Any material, compound, mixture, or preparation which contains any quantity of the
273 following substances:
274 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;
275 (b) Immediate precursors to phencyclidine (PCP):
276 a. 1-phenylcyclohexylamine;
277 b. 1-piperidinocyclohexanecarbonitrile (PCC).
278 5. The department of health and senior services shall place a substance in Schedule III
279 if it finds that:
280 (1) The substance has a potential for abuse less than the substances listed in Schedules
281 I and II;
282 (2) The substance has currently accepted medical use in treatment in the United States;
283 and
284 (3) Abuse of the substance may lead to moderate or low physical dependence or high
285 psychological dependence.
286 6. The controlled substances listed in this subsection are included in Schedule III:
287 (1) Any material, compound, mixture, or preparation which contains any quantity of the
288 following substances having a potential for abuse associated with a stimulant effect on the
289 central nervous system:
290 (a) Benzphetamine;
291 (b) Chlorphentermine;
292 (c) Clortermine;
293 (d) Phendimetrazine;
294 (2) Any material, compound, mixture or preparation which contains any quantity or salt
295 of the following substances or salts having a depressant effect on the central nervous system:
296 (a) Any material, compound, mixture or preparation which contains any quantity or salt
297 of the following substances combined with one or more active medicinal ingredients:
298 a. Amobarbital;
299 b. Secobarbital;
300 c. Pentobarbital;
301 (b) Any suppository dosage form containing any quantity or salt of the following:
302 a. Amobarbital;
303 b. Secobarbital;
304 c. Pentobarbital;

305 (c) Any substance which contains any quantity of a derivative of barbituric acid or its
306 salt;

307 (d) Chlorhexadol;

308 (e) Embutramide;

309 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in
310 a drug product for which an application has been approved under Section 505 of the federal
311 Food, Drug, and Cosmetic Act;

312 (g) Ketamine, its salts, isomers, and salts of isomers;

313 (h) Lysergic acid;

314 (i) Lysergic acid amide;

315 (j) Methypylon;

316 (k) Sulfondiethylmethane;

317 (l) Sulfonethylmethane;

318 (m) Sulfonmethane;

319 (n) Tiletamine and zolazepam or any salt thereof;

320 (3) Nalorphine;

321 (4) Any material, compound, mixture, or preparation containing limited quantities of any
322 of the following narcotic drugs or their salts:

323 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
324 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
325 of opium;

326 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
327 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized
328 therapeutic amounts;

329 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
330 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an
331 isoquinoline alkaloid of opium;

332 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
333 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic
334 ingredients in recognized therapeutic amounts;

335 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more
336 than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in
337 recognized therapeutic amounts;

338 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters
339 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic
340 ingredients in recognized therapeutic amounts;

341 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per
342 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more
343 active nonnarcotic ingredients in recognized therapeutic amounts;

344 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one
345 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic
346 amounts;

347 (5) Any material, compound, mixture, or preparation containing any of the following
348 narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;

349 (6) Anabolic steroids. Any drug or hormonal substance, chemically and
350 pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and
351 dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is
352 expressly intended for administration through implants to cattle or other nonhuman species and
353 which has been approved by the Secretary of Health and Human Services for that administration.
354 If any person prescribes, dispenses, or distributes such steroid for human use, such person shall
355 be considered to have prescribed, dispensed, or distributed an anabolic steroid within the
356 meaning of this paragraph. Unless specifically excepted or unless listed in another schedule, any
357 material, compound, mixture or preparation containing any quantity of the following substances,
358 including its salts, esters and ethers:

- 359 (a) $3\beta,17$ -dihydroxy-5 α -androsterane;
- 360 (b) $3\alpha,17\beta$ -dihydroxy-5 α -androsterane;
- 361 (c) 5 α -androsteran-3,17-dione;
- 362 (d) 1-androstenediol ($3\beta,17\beta$ -dihydroxy-5 α -androster-1-ene);
- 363 (e) 1-androstenediol ($3\alpha,17\beta$ -dihydroxy-5 α -androster-1-ene);
- 364 (f) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene);
- 365 (g) 5-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-5-ene);
- 366 (h) 1-androstenedione ([5 α]-androster-1-en-3,17-dione);
- 367 (i) 4-androstenedione (androster-4-en-3,17-dione);
- 368 (j) 5-androstenedione (androster-5-en-3,17-dione);
- 369 (k) Bolasterone (7 α , 17 α -dimethyl-17 β -hydroxyandroster-4-en-3-one);
- 370 (l) Boldenone (17 β -hydroxyandroster-1,4,-diene-3-one);
- 371 (m) Calusterone (7 β , 17 α -dimethyl-17 β -hydroxyandroster-4-en-3-one);
- 372 (n) Clostebol (4-chloro-17 β -hydroxyandroster-4-en-3-one);
- 373 (o) Dehydrochloromethyltestosterone (4-chloro-17 β -hydroxy-17 α -methyl-androst-1,4-
374 dien-3-one);
- 375 (p) Δ^1 -dihydrotestosterone (a.k.a. '1-testosterone')(17 β -hydroxy-5 α -androster-1-en-3-one);
- 376 (q) 4-dihydrotestosterone (17 β -hydroxy-androsteran-3-one);

- 377 (r) Drostanolone (17 β -hydroxy-2 α -methyl-5 α -androstan-3-one);
 378 (s) Ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);
 379 (t) Fluoxymesterone (9-fluoro-17 α -methyl-11 β ,17 β -dihydroxyandrost-4-en-3-one);
 380 (u) Formebolone (2-formyl-17 α -methyl-11 α ,17 β -dihydroxyandrost-1,4-dien-3-one);
 381 (v) Furazabol (17 α -methyl-17 β -hydroxyandrostano[2,3-c]-furazan);
 382 (w) 13 β -ethyl-17 β -hydroxygon-4-en-3-one;
 383 (x) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-one);
 384 (y) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one);
 385 (z) Mestanolone (17 α -methyl-17 β -hydroxy-5 α -androstan-3-one);
 386 (aa) Mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-one);
 387 (bb) Methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);
 388 (cc) Methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-ene);
 389 (dd) Methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one);
 390 (ee) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstan-3-one);
 391 (ff) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstan-3-one);
 392 (gg) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene;
 393 (hh) 17 α -methyl-4-hydroxynandrolone (17 α -methyl-4-hydroxy-17 β -hydroxyestr-4-en-3-
 394 one);
 395 (ii) Methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
 396 (jj) Methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9,11-trien-3-one);
 397 (kk) Methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);
 398 (ll) Mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);
 399 (mm) 17 α -methyl- Δ 1-dihydrotestosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-
 400 3-one) (a.k.a. '17- α -methyl-1-testosterone');
 401 (nn) Nandrolone (17 β -hydroxyestr-4-ene-3-one);
 402 (oo) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
 403 (pp) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
 404 (qq) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
 405 (rr) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
 406 (ss) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
 407 (tt) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
 408 (uu) Norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);
 409 (vv) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
 410 (ww) Norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);
 411 (xx) Normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);
 412 (yy) Oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstan-3-one);

413 (zz) Oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);
414 (aaa) Oxymethalone (17 α -methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-androst-3-
415 one);
416 (bbb) Stanozolol (17 α -methyl-17 β -hydroxy-[5 α]-androst-2-eno[3,2-c]-pyrazole);
417 (ccc) Stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);
418 (ddd) Testolactone (13-hydroxy-3-oxo-13,17-secoandrost-1,4-dien-17-oic acid lactone);
419 (eee) Testosterone (17 β -hydroxyandrost-4-en-3-one);
420 (fff) Tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-trien-3-one);
421 (ggg) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);
422 (hhh) Any salt, ester, or ether of a drug or substance described or listed in this
423 subdivision, except an anabolic steroid which is expressly intended for administration through
424 implants to cattle or other nonhuman species and which has been approved by the Secretary of
425 Health and Human Services for that administration;
426 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
427 United States Food and Drug Administration approved drug product;
428 (8) The department of health and senior services may except by rule any compound,
429 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions
430 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to
431 195.320 if the compound, mixture, or preparation contains one or more active medicinal
432 ingredients not having a stimulant or depressant effect on the central nervous system, and if the
433 admixtures are included therein in combinations, quantity, proportion, or concentration that
434 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on
435 the central nervous system.
436 7. The department of health and senior services shall place a substance in Schedule IV
437 if it finds that:
438 (1) The substance has a low potential for abuse relative to substances in Schedule III;
439 (2) The substance has currently accepted medical use in treatment in the United States;
440 and
441 (3) Abuse of the substance may lead to limited physical dependence or psychological
442 dependence relative to the substances in Schedule III.
443 8. The controlled substances listed in this subsection are included in Schedule IV:
444 (1) Any material, compound, mixture, or preparation containing any of the following
445 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
446 as set forth below:
447 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms
448 of atropine sulfate per dosage unit;

449 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-
450 propionoxybutane);

451 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall
452 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer
453 upon the compound, mixture or preparation valuable medicinal qualities other than those
454 possessed by the narcotic drug alone:

455 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per
456 one hundred grams;

457 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters
458 or per one hundred grams;

459 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters
460 or per one hundred grams;

461 (2) Any material, compound, mixture or preparation containing any quantity of the
462 following substances, including their salts, isomers, and salts of isomers whenever the existence
463 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

464 (a) Alprazolam;

465 (b) Barbitol;

466 (c) Bromazepam;

467 (d) Camazepam;

468 (e) Chloral betaine;

469 (f) Chloral hydrate;

470 (g) Chlordiazepoxide;

471 (h) Clobazam;

472 (i) Clonazepam;

473 (j) Clorazepate;

474 (k) Clotiazepam;

475 (l) Cloxazolam;

476 (m) Delorazepam;

477 (n) Diazepam;

478 (o) Dichloralphenazone;

479 (p) Estazolam;

480 (q) Ethchlorvynol;

481 (r) Ethinamate;

482 (s) Ethyl loflazepate;

483 (t) Fludiazepam;

484 (u) Flunitrazepam;

485 (v) Flurazepam;
486 (w) Halazepam;
487 (x) Haloxazolam;
488 (y) Ketazolam;
489 (z) Loprazolam;
490 (aa) Lorazepam;
491 (bb) Lormetazepam;
492 (cc) Mebutamate;
493 (dd) Medazepam;
494 (ee) Meprobamate;
495 (ff) Methohexital;
496 (gg) Methylphenobarbital (mephobarbital);
497 (hh) Midazolam;
498 (ii) Nimetazepam;
499 (jj) Nitrazepam;
500 (kk) Nordiazepam;
501 (ll) Oxazepam;
502 (mm) Oxazolam;
503 (nn) Paraldehyde;
504 (oo) Petrichloral;
505 (pp) Phenobarbital;
506 (qq) Pinazepam;
507 (rr) Prazepam;
508 (ss) Quazepam;
509 (tt) Temazepam;
510 (uu) Tetrazepam;
511 (vv) Triazolam;
512 (ww) Zaleplon;
513 (xx) Zolpidem;
514 (yy) Zopiclone;

515 (3) Any material, compound, mixture, or preparation which contains any quantity of the
516 following substance including its salts, isomers and salts of isomers whenever the existence of
517 such salts, isomers and salts of isomers is possible: fenfluramine;

518 (4) Any material, compound, mixture or preparation containing any quantity of the
519 following substances having a stimulant effect on the central nervous system, including their
520 salts, isomers and salts of isomers:

- 521 (a) Cathine ((+)-norpseudoephedrine);
522 (b) Diethylpropion;
523 (c) Fencamfamin;
524 (d) Fenproporex;
525 (e) Mazindol;
526 (f) Mefenorex;
527 (g) Modafinil;
528 (h) Pemoline, including organometallic complexes and chelates thereof;
529 (i) Phentermine;
530 (j) Pipradrol;
531 (k) Sibutramine;
532 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
533 (5) Any material, compound, mixture or preparation containing any quantity of the
534 following substance, including its salts:
535 (a) butorphanol;
536 (b) pentazocine;
537 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance
538 is the only active medicinal ingredient;
539 (7) The department of health and senior services may except by rule any compound,
540 mixture, or preparation containing any depressant substance listed in subdivision (1) of this
541 subsection from the application of all or any part of sections 195.010 to 195.320 if the
542 compound, mixture, or preparation contains one or more active medicinal ingredients not having
543 a depressant effect on the central nervous system, and if the admixtures are included therein in
544 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the
545 substances which have a depressant effect on the central nervous system.
546 9. The department of health and senior services shall place a substance in Schedule V
547 if it finds that:
548 (1) The substance has low potential for abuse relative to the controlled substances listed
549 in Schedule IV;
550 (2) The substance has currently accepted medical use in treatment in the United States;
551 and
552 (3) The substance has limited physical dependence or psychological dependence liability
553 relative to the controlled substances listed in Schedule IV.
554 10. The controlled substances listed in this subsection are included in Schedule V:
555 (1) Any compound, mixture or preparation containing any of the following narcotic
556 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set

557 forth below, which also contains one or more nonnarcotic active medicinal ingredients in
558 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal
559 qualities other than those possessed by the narcotic drug alone:

560 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
561 twenty-five micrograms of atropine sulfate per dosage unit;

562 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per
563 one hundred grams;

564 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
565 micrograms of atropine sulfate per dosage unit;

566 (2) Any material, compound, mixture or preparation which contains any quantity of the
567 following substance having a stimulant effect on the central nervous system including its salts,
568 isomers and salts of isomers: pyrovalerone;

569 (3) Any compound, mixture, or preparation containing any detectable quantity of
570 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,
571 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical
572 isomers, or salts of optical isomers;

573 (4) Unless specifically exempted or excluded or unless listed in another schedule, any
574 material, compound, mixture, or preparation which contains any quantity of the following
575 substances having a depressant effect on the central nervous system, including its salts:
576 pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].

577 11. If any compound, mixture, or preparation as specified in subdivision (3) of
578 subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a
579 prescription:

580 (1) All packages of any compound, mixture, or preparation containing any detectable
581 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,
582 its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind
583 a pharmacy counter where the public is not permitted, and only by a registered pharmacist or
584 registered pharmacy technician; and

585 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,
586 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,
587 or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers
588 shall be at least eighteen years of age; and

589 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require
590 any person, prior to their purchasing, receiving or otherwise acquiring such compound, mixture,
591 or preparation to furnish suitable photo identification that is issued by a state or the federal

592 government or a document that, with respect to identification, is considered acceptable and
593 showing the date of birth of the person;

594 (4) The seller shall deliver the product directly into the custody of the purchaser.

595 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall
596 implement and maintain an electronic log of each transaction. Such log shall include the
597 following information:

598 (1) The name, address, and signature of the purchaser;

599 (2) The amount of the compound, mixture, or preparation purchased;

600 (3) The date and time of each purchase; and

601 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy
602 technician who dispensed the compound, mixture, or preparation to the purchaser.

603 13. Each pharmacy shall submit information regarding sales of any compound, mixture,
604 or preparation as specified in subdivision (3) of subsection 10 of this section in accordance with
605 transmission methods and frequency established by the department by regulation;

606 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities
607 greater than those specified in this chapter.

608 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products
609 in a pharmacy shall ensure that all such products are located only behind a pharmacy counter
610 where the public is not permitted.

611 16. Any person who knowingly or recklessly violates the provisions of subsections 11
612 to 15 of this section is guilty of a class A misdemeanor.

613 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this
614 section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,
615 mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound,
616 mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must
617 be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.

618 18. The manufacturer of a drug product or another interested party may apply with the
619 department of health and senior services for an exemption from this section. The department of
620 health and senior services may grant an exemption by rule from this section if the department
621 finds the drug product is not used in the illegal manufacture of methamphetamine or other
622 controlled or dangerous substances. The department of health and senior services shall rely on
623 reports from law enforcement and law enforcement evidentiary laboratories in determining if the
624 proposed product can be used to manufacture illicit controlled substances.

625 19. The department of health and senior services shall revise and republish the schedules
626 annually.

627 20. The department of health and senior services shall promulgate rules under chapter
628 536, RSMo, regarding the security and storage of Schedule V controlled substances, as described
629 in subdivision (3) of subsection 10 of this section, for distributors as registered by the department
630 of health and senior services.

631 21. Logs of transactions required to be kept and maintained by this section and section
632 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is
633 the person whose transactions are recorded in the logs.

✓